A
Apurva Prakash
Researcher at Eli Lilly and Company
Publications - 28
Citations - 1995
Apurva Prakash is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Duloxetine & Placebo. The author has an hindex of 21, co-authored 26 publications receiving 1735 citations.
Papers
More filters
Journal ArticleDOI
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez,Adam L Reinhardt,Suzanne E. Ramsey,Helmut Wittkowski,Philip J. Hashkes,Yackov Berkun,Susanne Schalm,Sara Murias,Jason Dare,Diane Brown,Deborah L. Stone,Ling Gao,Thomas Klausmeier,Dirk Foell,Adriana Almeida de Jesus,Dawn Chapelle,Hanna Kim,Samantha Dill,Robert A. Colbert,Laura Failla,B. Kost,Michelle O'Brien,James C. Reynolds,Les R. Folio,Katherine R. Calvo,Scott M. Paul,Nargues Weir,Alessandra Brofferio,Ariane Soldatos,Angelique Biancotto,Edward W. Cowen,John J. Digiovanna,Massimo Gadina,Andrew Lipton,Colleen Hadigan,Steven M. Holland,Joseph A. Fontana,Ahmad Samer Alawad,Rebecca J. Brown,Kristina I. Rother,Theo Heller,Kristina M Brooks,Parag Kumar,Stephen R. Brooks,Meryl Waldman,Harsharan K. Singh,Volker Nickeleit,Maria Silk,Apurva Prakash,Jonathan Janes,Seza Ozen,Paul G. Wakim,Paul A. Brogan,William L. Macias,Raphaela Goldbach-Mansky +54 more
TL;DR: Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies CANDLE, SAVI, and other interfer onopathies.
Journal ArticleDOI
The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders.
TL;DR: An anchor-based value is determined for the change in the worst, least, and average pain intensity items of the Brief Pain Inventory that best represents a clinically important difference in clinical trials of chronic-pain therapies.
Journal ArticleDOI
Fluoxetine Versus Placebo in Posttraumatic Stress Disorder
TL;DR: Fluoxetine is effective and well tolerated in the treatment of PTSD, and most PTSD patients will respond satisfactorily at doses in the upper normal range for the usual antidepressant doses of fluoxettine.
Journal ArticleDOI
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Andrew A. Nierenberg,John H. Greist,Craig H. Mallinckrodt,Apurva Prakash,Angelo Sambunaris,Gary D. Tollefson,Madelaine M. Wohlreich +6 more
TL;DR: Both duloxetine and escitalopram showed significantly greater improvement on the primary efficacy measure than placebo over the 8‑week acute treatment period, while no differences were observed between drugs or between drugs and placebo on response and remission rates at 8 weeks.
Journal ArticleDOI
ORIGINAL RESEARCH—PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder
Anita H. Clayton,Susan G. Kornstein,Apurva Prakash,Craig H. Mallinckrodt,Madelaine M. Wohlreich +4 more
TL;DR: Regardless of treatment, patients who achieved remission of MDD showed improvement in global sexual functioning, whereas worsening was observed for patients who did not achieve remission; however, MDD outcome (regardless of treatment) had a significant impact on improvement inglobal sexual functioning.